drugset / Trial / NCT04453345

Summary

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy. So the investigators put them together as LGLL. The investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response. Adverse events (AE) of grade 3 and above are rare and safe. Therefore, the investigators designed this multicenter clinical trial to validate the efficacy of the TPM regimen in symptomatic T-LGLL and CLPD-NK.

Timeline

Start
2013-05-20
Primary completion
2023-05-20
Completion
2025-05-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 10 mg/m2
Subject Prednisone Other / unclassified 0.5 mg/kg
Subject Prednisone Other / unclassified 1 mg/kg
Subject Thalidomide Other / unclassified 50 mg
Subject Thalidomide Other / unclassified 100 mg